Impact of smart watch mobile application on the risk treatment of type 2 diabetes mellitus (iSMART-DM)
Primary Care Diabetes · 2026
DOI: 10.1016/j.pcd.2025.10.008 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Primary Care Diabetes, 2026. Verfasst von Min Kyoung Jang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Mobile Applications, Blood Glucose, Glycemic Control. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Non-US Government Research Support type.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: d100583@amc.seoul.kr.
Förderung
- Non-US Government Research Support type
Zitieren
APA
Jang, M. K., Cho, Y. K., Moon, J. Y., Min, S. H., Hwang, J. H., & Jung, C. H. (2026). Impact of smart watch mobile application on the risk treatment of type 2 diabetes mellitus (iSMART-DM). Primary Care Diabetes. https://doi.org/10.1016/j.pcd.2025.10.008
Vancouver
Jang MK, Cho YK, Moon JY, Min SH, Hwang JH, Jung CH. Impact of smart watch mobile application on the risk treatment of type 2 diabetes mellitus (iSMART-DM). Primary Care Diabetes. 2026. doi:10.1016/j.pcd.2025.10.008
BibTeX
@article{Jang2026,
author = {Jang, Min Kyoung and Cho, Yun Kyung and Moon, Jung Yoon and Min, Se Hee and Hwang, Ju Hee and Jung, Chang Hee},
title = {Impact of smart watch mobile application on the risk treatment of type 2 diabetes mellitus (iSMART-DM)},
journal = {Primary Care Diabetes},
year = {2026},
doi = {10.1016/j.pcd.2025.10.008}
}
EUVIMED